Literature DB >> 2935965

The measurement of heparin and other therapeutic sulphated polysaccharides in plasma, serum and urine.

J Dawes, C V Prowse, D S Pepper.   

Abstract

The competitive binding assay described will specifically and accurately measure concentrations of administered heparin in biological fluids with a sensitivity of 60 ng ml-1. Neither endogenous glycosaminoglycans, nor plasma proteins such as ATIII and PF4 interfere in the assay. Semi-synthetic highly sulphated heparinoids and LMW heparin can also be measured. Using this assay heparin clearance followed simple first-order kinetics over the dose range 100-5,000 units, but the half-life was strongly dose-dependent. There was good correlation with heparin activity measurements by APTT and anti-Xa clotting assays. Plasma concentrations were measurable for at least 5 h following subcutaneous injection of 10,000 units of heparin. Excretion in the urine could be followed after all but the lowest intravenous dose. This assay, used in conjunction with measurements of heparin anticoagulant activity, will be valuable in the elucidation of mechanisms of action of heparin and the heparinoids, and in the assessment and management of problems related to heparin therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2935965

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.

Authors:  J C Stiekema; H P Wijnand; T G Van Dinther; H C Moelker; J Dawes; A Vinchenzo; H Toeberich
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

2.  Desulphation of dextran sulphate during kidney ultrafiltration.

Authors:  W D Comper; M Tay; X Wells; J Dawes
Journal:  Biochem J       Date:  1994-01-01       Impact factor: 3.857

3.  Plasma concentrations of endogenous heparinoids in portal hypertension.

Authors:  R F McKee; S Hodson; J Dawes; O J Garden; D C Carter
Journal:  Gut       Date:  1992-11       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.